Polyethylene Glycol Versus Senna for Bowel Preparation for Colonoscopy in Children: Updated Evidence by a Systematic Review and Meta-Analysis

Jun Watanabe 1, Kazuhiko Kotani 1

1. Community and Family Medicine, Jichi Medical University, Shimotsuke, JPN

Corresponding author: Kazuhiko Kotani, kazukotani@jichi.ac.jp

Abstract

For colonoscopy, bowel preparation, especially that using polyethylene glycol (PEG) or senna, is performed among children with gastrointestinal disorders; however, it is not fully grounded in evidence. This study reviewed via meta-analyses the approaches to bowel preparation for colonoscopy in children.

Electronic databases and trial registries were searched until April 2021. Quality assessment was conducted using the Grading of Recommendations, Assessment, Development, and Evaluation method.

In total, three randomized controlled trials (318 patients) were identified. PEG was observed as a preferred protocol of bowel preparation compared with senna (risk ratio [RR] 1.35, 95% confidence interval [CI] 1.05-1.74; I² = 15%). It was less painful than senna (RR 0.62, 95% CI 0.44-0.87; I² = 0%). No serious adverse events were noted. Overall, the certainty of the evidence was low to moderate.

PEG might be a preferred preparation agent for colonoscopy in children. Given the limited data, more studies are recommended.

Introduction And Background

Gastrointestinal disorders are commonly seen in children, and colonoscopy is considered the gold standard for diagnosis and treatment of patients with gastrointestinal disorders [1]. For example, colonoscopy is performed in children with inflammatory bowel disease, bleeding colitis, colon polyps, and malignancies [2-5]. Inadequate bowel preparation is known to adversely affect the colonoscopy procedure [6,7]. Bowel preparation is reported to be inadequate in one-third of colonoscopies and in approximately 5% of cases, and inadequate preparation led to cancellation or interruption of the examination [8]. The cost of cancelled or interrupted examinations has increased from 12% to 22% [9,10]. Even if bowel preparation is performed with consideration of the patient’s age, body size, and medical condition [1,11], a standard protocol for bowel preparation for children with gastrointestinal disorders is required.

In the clinical setting, osmotic drugs (i.e., polyethylene glycol) and stimulant laxatives (i.e., senna) are empirically used. Regarding the standard protocol for bowel preparation, an earlier systematic review [12] with three randomized controlled trials (RCTs) [13-15] reported that polyethylene glycol and senna demonstrated similar efficacies for bowel preparation before colonoscopy in children. However, that review [12] included one study [13] in which magnesium citrate, not senna, was compared to polyethylene glycol. After that review [12], new findings from an RCT have also been reported [16]. Thus, in order to update our knowledge concerning the use of polyethylene glycol and senna for colonoscopy, we reviewed via a meta-analysis the efficacy of polyethylene glycol compared to senna for bowel preparation before colonoscopy in children.

Review

Study selection and outcomes

This study followed the preferred reporting items for systematic review and meta-analysis 2020 (PRISMA-2020) [17]. Inclusion criteria were RCTs that compared the use of polyethylene glycol versus senna in bowel preparation for colonoscopy in children with gastrointestinal disorders. The dosage of polyethylene glycol and senna were 1-3 g/kg/day and 1-3 mg/kg/day during 1-3 days, respectively. No restrictions to language, country, observation period, or publication year were applied. Exclusion criteria were studies on patients above 18 years or using non-colonoscopic procedures, such as flexible sigmoidoscopy, computed tomography-colonography, and capsule endoscopy. The primary outcomes were quality of bowel
preparation and the number of patients with abdominal pain. The secondary outcome were all adverse events. The definition of adverse events was based on the guidelines [1,6,7]. Serious adverse events were defined as those requiring additional medication [1,6,7]. Preferred bowel preparation was defined as the number of patients with a score of excellent or good as assessed by the endoscopist, with at least 90% of the mucosa visible [18], corresponding to an excellent level on the Ottawa bowel preparation scale [19] and an excellent or good level on the Aronchick scale [20].

The following databases were searched: MEDLINE via PubMed, the Cochrane Central Register of Controlled Trials via Cochrane Library, Embase via Dialog, the World Health Organization International Clinical Trials Platform Search Portal (ICTRP) and ClinicalTrials.gov (Appendix 1). The reference lists of studies were checked with the international guidelines [1,6,7]. The studies were included in the lists if eligible RCTs cited the studies necessary for this review.

Data collection, the assessment of the risk of bias, and the analyses
Titles and abstracts were screened by independent reviewers, followed by an assessment of the eligibility based on the full text. Disagreements between reviewers were resolved by discussion. Data extraction and the risk of bias in the included studies were independently evaluated using the Risk of Bias 2 [21]. Disagreements between reviewers were discussed.

The relative risk ratios (RRs) and 95% confidence intervals (CIs) were pooled for the preferred bowel preparation and abdominal pain. An intention-to-treat analysis for all dichotomous data was performed. A random-effects meta-analysis was performed using a freely available software program, Review Manager (RevMan 5.4.1). Adverse events were summarized based on the definition used in the original article.

The assessment of heterogeneity, reporting bias, and certainty of evidence
The statistical heterogeneity was assessed by the visual inspection of the forest plots and analyzing the $I^2$ statistic ($I^2$ values of 0%-40%: may not be important; 50%-60%: potentially moderate heterogeneity; 50%-90%: potentially substantial heterogeneity; 75%-100%: considerable heterogeneity) [22]. In cases of substantial heterogeneity ($I^2 > 50%$), the reason for the heterogeneity was evaluated by a subgroup analysis of the dosing periods for polyethylene glycol (1 versus 2 days). A sensitivity analysis for excluding studies with a high risk of bias was performed to assess whether or not the results of the present review were robust. The correct analysis of the earlier review [12] for excluding studies with the wrong intervention [13] was performed to assess the consistency with the results in the present review.

Clinical trial registry systems (ClinicalTrials.gov and ICTRP) were searched, and an extensive literature search was conducted for unpublished trials. We did not perform funnel plots or the Egger test because there were fewer than 10 trials according to the Cochrane handbook [22]. The certainty of evidence was independently assessed based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [23]. A summary table of each study was made for the outcomes based on the Cochrane handbook [22].

Results
Figure 1 shows the flow chart of the article search. A total of 601 records were searched on April 21, 2021. After the initial screening of the title and abstract, six records were identified. After the full-text screening, two studies were excluded because the study was conducted on adult patients [24] or the wrong intervention was performed [13]. Ultimately, three studies (318 participants) were identified [14-16]. Although the documents and the references of the initially included studies were searched, no additional studies that met the inclusion criteria were identified.
Table 1 summarizes the characteristics of the eligible studies. Two trials used polyethylene glycol for two days [14,15], while the other used it for one day [16]. Bowel preparation was evaluated by numeric rating scale in one study [15], the Aronchick scale in one study [14], Ottawa bowel preparation scale in two studies [14,16], and Boston bowel preparation scale in one study [16]. Table 2 and Table 3 show the risk of bias. Overall, the risk of bias in all studies was of some concern because the randomization process was not clearly described, and the study protocols were not fully registered.

| Authors [ref no.] | Year | Country | Subject no. (polyethylene glycol/senna) | Age (years) (polyethylene glycol/senna) | Dosing periods of polyethylene glycol (days) | Dosing periods of senna (days) |
|-------------------|------|---------|----------------------------------------|-----------------------------------------|--------------------------------------------|-----------------------------|
| Kierkus et al. [14]| 2013 | Poland  | 30 (16/14)                             | 14.1/14.2                               | 2                                          | 2                           |
| Terry et al. [15] | 2013 | USA     | 160 (80/80)                            | 12.3/13.3                               | 2                                          | 2                           |
| Tutar et al. [16] | 2019 | Turkey  | 128 (64/64)                            | 10.3/10.1                               | 1                                          | 3                           |

**TABLE 1: Summary of the characteristics of the eligibility studies**
TABLE 2: Quality scores for the eligibility studies for preferred bowel preparation

| Authors                  | Risk of Bias 2 tool assessment | Bias arising from the randomization process | Bias due to deviations from intended interventions | Bias due to missing outcome data | Bias in measurement of the outcome | Bias in selection of the reported results | Overall risk of bias |
|--------------------------|--------------------------------|---------------------------------------------|--------------------------------------------------|--------------------------------|-----------------------------------|------------------------------------------|---------------------|
| Kierkus et al. [14]      | Low                            | Low                                        | Low                                              | Low                             | Low                               | Some concerns                           | Low                 |
| Terry et al. [15]        | Some concerns                  | Low                                        | Low                                              | Low                             | Low                               | Some concerns                           | Some concerns       |
| Tutar et al. [16]        | Some concerns                  | Some concerns                              | Some concerns                                    | Low                             | Some concerns                      | Some concerns                           | Some concerns       |

TABLE 3: Quality scores of the eligibility studies for patients’ abdominal pain and adverse events

Outcomes
Table 4 shows the summary of findings using the GRADE approach [23]. Polyethylene glycol was found to be the preferred protocol of bowel preparation compared with senna (RR 1.35, 95% CI 1.05-1.74; I² = 15%) (Figure 2). The certainty of evidence was moderate because of imprecision due to the small sample size. Polyethylene glycol was also shown to be less painful than senna (RR 0.62, 95% CI 0.44-0.87; I² = 0%) (Figure 3). The certainty of evidence was low because of imprecision due to the small sample size and high risk of bias.
Polyethylene glycol versus senna for bowel preparation for colonoscopy in children

Patient or population: children, Setting: colonoscopy, Intervention: polyethylene glycol, Comparison: senna

### Outcomes

| Outcomes                  | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Patient number (studies) | Certainty of the evidence (GRADE) | Comments |
|---------------------------|---------------------------------------|--------------------------|--------------------------|----------------------------------|----------|
| Quality of bowel preparation | 405 per 1000 (425-705) | RR 1.35 (1.05-1.74) | 318 (3 RCTs) | Moderate<sup>a</sup> | Polyethylene glycol was observed as a preferred protocol of bowel preparation |
| Abdominal pain            | 380 per 1000 (167-330) | RR 0.62 (0.44-0.87) | 318 (3 RCTs) | Low<sup>a,b</sup> | Polyethylene glycol did not cause abdominal pain |
| Adverse events            | In three studies, both groups had similar untreated adverse events, such as nausea, vomiting, and sleep disorders between both groups | | 318 (3 RCTs) | Low<sup>a,b</sup> | No serious adverse events were observed |

**TABLE 4: Summary of findings**

CI, confidence interval; RR, risk ratio; GRADE, Grading of Recommendations Assessment, Development and Evaluation.

The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

<sup>a</sup>Downgraded because of imprecision due to the small sample size. <sup>b</sup>Downgraded because of imprecision due to high risk of bias.

---

In all three studies [14–16], the prevalence of adverse events such as nausea, vomiting, and sleep disturbances was similar between polyethylene glycol and senna. No serious adverse events requiring additional medication were observed. In addition, a subgroup analysis was not performed due to the lack of substantial heterogeneity (I² > 50%). The prespecified sensitivity analyses were consistent with the primary findings of the present review (Figure 4). Furthermore, the correct analysis of the earlier review was also consistent with the primary findings of the present review (Figure 5 and Figure 6).
FIGURE 4: Prespecified sensitivity analyses
CI, confidence interval; M-H, Mantel-Haenszel.

FIGURE 5: Correct analysis of preferred bowel preparation in excluding studies with a high risk of bias
CI, confidence interval; M-H, Mantel-Haenszel.

FIGURE 6: Correct analysis of abdominal pain in excluding studies with a high risk of bias
CI, confidence interval; M-H, Mantel-Haenszel.

Discussion
The present systematic review and meta-analysis suggested that polyethylene glycol might be a preferred preparation for colonoscopy in children with gastrointestinal disorders. As the evidence was moderate to low, the results should be interpreted with caution in the clinical setting. However, the updated findings of integrated RCTs on polyethylene glycol will further facilitate the establishment of a standard protocol for bowel preparation in children.

The earlier systematic review [12] reported a similar efficacy for preparing the bowel for colonoscopy between polyethylene glycol and senna (RR 0.73, 95% CI 0.31-1.76; I² = 95%) according to pooled data. Here, we reconsidered one study that did not compare polyethylene glycol and senna [13] in that review [12] and further added a recent study that favored polyethylene glycol over senna [16]. Thus, the results of this updated systematic review differed from the previous review.

In bowel preparation of polyethylene glycol and senna, abdominal-related symptoms such as abdominal pain and the others (e.g., nausea, vomiting) can adversely appear [14-16]. The present review showed that such events were mildly observed in some cases, and none required nasogastric tube placement or hospitalization. These results were similarly reported to the previous review [12]. On the other hand, the present review found that senna leads to a higher incidence of abdominal pain than that of polyethylene glycol [14-16]. This may be explained by the fact that senna is a laxative that stimulates the movement of the intestinal tract and can induce abdominal pain [24]. Some previous studies on children also reported a high incidence of abdominal pain by senna [25-28]. Empirically, even though both polyethylene glycol and senna have been safely used for children and no serious adverse events were noted, we should be careful about abdominal pain as induced by senna.

There have been several bowel preparation quality scores. The most well-established and popularly used validated scores include the Aronchick scale [20], Boston bowel preparation scale [29], and Ottawa bowel
preparation scale [19]. Although a previous review [29,30] described that the Boston bowel preparation scale should be used in clinical practice, all scales had the several limitations. Comparisons between these scales would be still needed for bowel preparation using polyethylene glycol in children.

The limitations associated with the present study warrant mention. First, as mentioned above, the sample size was not very large, although a rigorous methodology was adopted based on the PRISMA statement [17]. Second, the studies reviewed used different doses and dosing periods, although the heterogeneity for all studies was not shown. Third, the risk of bias in all studies reviewed was of some concern because the randomization approaches and protocols were not detailed. Further studies will be required to increase the certainty and generalizability of the evidence.

Conclusions

We reviewed using a meta-analysis to assess the efficacy of polyethylene glycol and senna in bowel preparation before colonoscopy in children. Our review provided updated evidence suggesting that polyethylene glycol might be the preferred agent for use in bowel preparation before colonoscopy in children. The present study updated our knowledge on the use of polyethylene glycol and senna for colonoscopy. More studies, including RCTs, are needed to establish the efficacy of polyethylene glycol given the limited number of available studies for review.

Appendices

Appendix 1. Search strategy

CENTRAL

#1. MeSH descriptor: [Colonoscopy] explode all trees

#2. colonoscop*:ti,ab,kw (Word variations have been searched)

#3. #1 OR #2

#4. MeSH descriptor: [Infant] explode all trees

#5. MeSH descriptor: [Child] explode all trees

#6. MeSH descriptor: [Adolescent] explode all trees

#7. (infant* OR child* OR pediatric* OR paediatric* OR adolescent* OR neonat* OR toddler OR young):ti,ab,kw (Word variations have been searched)

#8. #4 OR #5 OR #6 OR #7

#9. MeSH descriptor: [Cathartics] explode all trees

#10. MeSH descriptor: [Cathartics] explode all trees

#11. MeSH descriptor: [Polyethylene Glycols] explode all trees

#12. MeSH descriptor: [Sennosides] explode all trees

#13. (Cathartics OR laxative OR "colon lavage" OR "intestine preparation"):ti,ab,kw (Word variations have been searched)

#14. (PEG OR polyethylene OR macrocol OR movicol OR idrolax OR miralax OR transipeg OR forlax OR colyte OR golytely OR isocolan OR nulytely):ti,ab,kw (Word variations have been searched)

#15. (Senna OR Sennosides):ti,ab,kw (Word variations have been searched)

#16. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15

#17. #3 AND #8 AND #16

MEDLINE
#1. Colonoscopy[Mesh]

#2. Colonoscop*[tiab]

#3. #1 OR #2

#4. Infant[Mesh]

#5. Child[Mesh]

#6. Adolescent[Mesh]

#7. (infant*[tiab] OR child*[tiab] OR pediatric*[tiab] OR paediatric*[tiab] OR adolescent*[tiab] OR neonat*[tiab] OR toddler*[tiab] OR young*[tiab])

#8. #4 OR #5 OR #6 OR #7 OR #8

#9. Cathartics[Mesh]

#10. "laxative*[tiab]

#11. "Polyethylene Glycols*[tiab]

#12. Sennosides[Mesh]

#13. Cathartics*[tiab] OR laxative*[tiab] OR "colon lavage*[tiab] OR "intestine preparation*[tiab]

#14. (PEG*[tiab] OR polyethylene*[tiab] OR macrogol*[tiab] OR movicol*[tiab] OR idro lax*[tiab] OR miralax*[tiab] OR transipeg*[tiab] OR forlax*[tiab] OR colyte*[tiab] OR golyte*[tiab] OR isocolan*[tiab] OR nulytely*[tiab])

#15. Senna*[tiab] OR Sennosides*[tiab]

#16. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15

#17. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR drug therapy[sh] OR placebo [tiab] OR randomly*[tiab] OR trial*[tiab] OR groups*[tiab]) NOT (animals [mh] NOT humans [mh])

#18. #3 AND #8 AND #16 AND #17

Embase

S1. EMB.EXACT.EXPLODE(“colonoscopy”)  
S2. ti(colonoscopy) OR ab(colonoscopy)  
S3. S1 OR S2  
S4. EMB.EXACT.EXPLODE(“child”)  
S5. EMB.EXACT.EXPLODE(“adolescent”)  
S6. ab(infant OR child OR pediatric OR paediatric OR adolescent OR neonat OR toddler OR young) OR ti(infant OR child OR pediatric OR paediatric OR adolescent OR neonat OR toddler OR young)  
S7. S4 OR S5 OR S6  
S8. EMB.EXACT.EXPLODE(“laxative”)  
S9. EMB.EXACT.EXPLODE(“macrogol derivative”)  
S10. EMB.EXACT.EXPLODE(“Senna”)
S11. ab(PEG OR polyethylene OR macrogl OR movicol OR idrolax OR transipeg OR forlax OR collute OR golytely OR isocolan OR nulytely) OR ti(PEG OR polyethylene OR macrogl OR movicol OR idrolax OR transipeg OR forlax OR collute OR golytely OR isocolan OR nulytely)

S12. ab(Senna OR Sennosides) OR ti(Senna OR Sennosides)

S13. S8 OR S9 OR S10 OR S11 OR S12

S14. S3 AND S7 AND S13

S15. (ab(random*) OR ti(random*)) OR (ab(placebo*) OR ti(placebo*)) OR (ab(double NEAR/1 blind*) OR ti(double NEAR/1 blind*))

S16. S14 AND S15

ClinicalTrial.gov
Colonoscopy AND (PEG OR polyethylene OR macrogl OR movicol OR idrolax OR transipeg OR forlax OR collute OR golytely OR isocolan OR nulytely) AND (Senna OR Sennosides)

ICTRP
Colonoscopy AND (PEG OR polyethylene OR macrogl OR movicol OR idrolax OR transipeg OR forlax OR collute OR golytely OR isocolan OR nulytely) AND (Senna OR Sennosides)

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Pall H, Zacur GM, Kramer RE, et al.: Bowel preparation for pediatric colonoscopy: report of the NASPghan endoscopy and procedures committee. J Pediatr Gastroenterol Nutr. 2014, 59:409-16. 10.1097/MPG.0000000000000447
2. Hood B, Bigler S, Bishop P, Liu H, Ahmad N, Renault M, Nowicki M: Juvenile polyps and juvenile polyp syndromes in children: a clinical and endoscopic survey. Clin Pediatr (Phila). 2011, 50:910-5. 10.1177/0009922811407177
3. Romano C, Oliva S, Martellotti S, et al.: Pediatric gastrointestinal bleeding: perspectives from the Italian Society of Pediatric Gastroenterology. World J Gastroenterol. 2017, 23:1528-37. 10.3748/wjg.v25.i8.1528
4. Daniel R, Lieb J 2nd, Pascasio J, Pall H: Diagnosis of serrated polyposis syndrome in an adolescent patient. Clin Pediatr (Philad). 2019, 58:364-6. 10.1177/0009922818812476
5. Wren AA, Maddux MH: Integrated multidisciplinary treatment for pediatric inflammatory bowel disease. Children (Basel). 2021, 8:169. 10.3390/children8020169
6. Johnson DA, Barkun AN, Cohen LB, et al.: Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. multi-society task force on colorectal cancer. Gastrointest Endosc. 2014, 80:545-62. 10.1016/j.gie.2014.08.002
7. Hassan C, East J, Radaelli F, et al.: Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 2019, 51:775-94. 10.1055/a-0959-0505
8. Ness RM, Manam R, Hoen H, Chalasani N: Predictors of inadequate bowel preparation for colonoscopy. Am J Gastroenterol. 2001, 96:1797-802. 10.1111/j.1572-0241.2001.03874.x
9. Rex DK, Impeotiale TF, Latinovich DR, Bratcher LL: Impact of bowel preparation on efficiency and cost of colonoscopy. Am J Gastroenterol. 2002, 97:1696-700. 10.1111/j.1572-0241.2002.05827.x
10. Sim JS, Koo JH: Predictors of inadequate bowel preparation and salvage options on colonoscopy. Clin Endosc. 2016, 49:546-9. 10.5966/cen.2016.094
11. Trautwein AL, Vinitski LA, Peck SN: Bowel preparation before colonoscopy in the pediatric patient: a randomized study. Gastroenterol Nurs. 1996, 19:157-9. 10.1097/00001610-199607000-00004
12. Gordon M, Karlsen F, Isaji S, Teck GO: Bowel preparation for elective procedures in children: a systematic review and meta-analysis. BMJ Paediatr Open. 2017, 1:e000118. 10.1136/bmjpo-2017-000118
13. Dahshan A, Lin CH, Peters J, Thomas R, Tolia V: A randomized, prospective study to evaluate the efficacy
and acceptance of three bowel preparations for colonoscopy in children. Am J Gastroenterol. 1999, 94:5497-501. 10.1111/j.1572-0241.1999.01613.x

14. Kierkus J, Horvath A, Szychta M, et al.: High- versus low-volume polyethylene glycol plus laxative versus sennosides for colonoscopy preparation in children. J Pediatr Gastroenterol Nutr. 2015, 57:230-5. 10.1097/MPG.0b013e5825959fe5

15. Terry NA, Chen-Lim ML, Ely E, et al.: Polyethylene glycol powder solution versus senna for bowel preparation for colonoscopy in children. J Pediatr Gastroenterol Nutr. 2013, 56:215-9. 10.1097/MPG.0b013e5825a63b5b

16. Tutar E, Bayrak NA, Volkun B, Ertem D: Bowel preparation for colonoscopy in children: 1 day PEG-3350 with bisacodyl versus 3 day sennosides. Dig Dis. 2019, 37:334-42. 10.1159/000497819

17. Page MJ, McKenzie JI, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71

18. Kastenberg D, Bertiger G, Brogadir S: Bowel preparation quality scales for colonoscopy. World J Gastroenterol. 2018, 24:2833-3. 10.3748/wjg.v24.i26.2833

19. Rostom A, Jolicoeur E: Validation of a new scale for the assessment of bowel preparation quality. Gastrointest Endosc. 2004, 59:482-6. 10.1016/s0016-5107(03)02875-x

20. Aronchick CA: Bowel preparation scale. Gastrointest Endosc. 2004, 60:1037-9. 10.1016/s0016-5107(04)02213-8

21. Sterne JA, Savović J, Page MJ, et al.: RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136/bmj.l4898

22. Higgins JPT, Thomas J: Cochrane Handbook for Systematic Reviews of Interventions Version 6. 2. 2021 .

23. Guyatt G, Oxman AD, Akl EA, et al.: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016/j.jclinepi.2010.04.026

24. Shavakhi A, Kianinia M, Torabi G, et al.: High dose senna or polyethylene glycol (PEG) for elective colonoscopy preparation: a prospective randomized investigator-blinded clinical trial. J Res Med Sci. 2011, 16:149-55.

25. Gorden M, Naidoo K, Akobeng AK, Thomas AG: Cochrane Review: osmotic and stimulant laxatives for the management of childhood constipation (Review). Evid Based Child Health. 2013, 8:57-109. 10.1002/ebch.1893

26. Santos-Jasso KA, Arredondo-García JL, Maza-Vallejos J, Lezama-Del Valle P: Effectiveness of senna vs polyethylene glycol as laxative therapy in children with constipation related to anorectal malformation. J Pediatr Surg. 2017, 52:84-8. 10.1016/j.jpedsurg.2016.10.021

27. Vilanova-Sanchez A, Gasior AC, Toochek N, et al.: Are senna based laxatives safe when used as long term treatment for constipation in children?. J Pediatr Surg. 2018, 53:722-7. 10.1016/j.jpedsurg.2018.01.002

28. Kesavelu D Sr: The efficacy and safety of combined senna and probiotic-based bowel preparation for colonoscopy in children. Cureus. 2020, 12:e10180. 10.7759/cureus.10180

29. Rutherford CC, Calderwood AH: Update on bowel preparation for colonoscopy. Curr Treat Options Gastroenterol. 2018, 16:165-81. 10.1007/s11938-018-0165-3

30. Parmar R, Martel M, Rostom A, Barkun AN: Validated scales for colon cleansing: a systematic review. Am J Gastroenterol. 2016, 111:197-204; quiz 205. 10.1038/aig.2015.417